<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823849</url>
  </required_header>
  <id_info>
    <org_study_id>246-08-802-01</org_study_id>
    <nct_id>NCT00823849</nct_id>
  </id_info>
  <brief_title>Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker</brief_title>
  <official_title>A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Beijing Research Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Beijing Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on&#xD;
           atherosclerosis related biomarker&#xD;
&#xD;
        2. To evaluate the safety of Cilostazol and Probucol alone and in combination on&#xD;
           atherosclerosis related biomarker&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy evaluation:&#xD;
&#xD;
      Primary efficacy index:&#xD;
&#xD;
      After 12 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality&#xD;
      groups, comparing with the base line information&#xD;
&#xD;
      Secondary efficacy index:&#xD;
&#xD;
      After 8 weeks of treatment, the change of arteriosclerosis related biomarker in 4 modality&#xD;
      groups, comparing with the base line information&#xD;
&#xD;
      Safety evaluation:&#xD;
&#xD;
        1. Adverse Event&#xD;
&#xD;
        2. Vital Sign and Physical Examination&#xD;
&#xD;
        3. 12-lead ECG&#xD;
&#xD;
        4. Laboratory Tests (including blood routine examination, routine urine analysis, blood&#xD;
           biochemistry examination, glycosylated hemoglobin)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Evaluation: Comparing with the basic line information, the change value of arteriosclerosis related biomarker in 4 groups after 12 weeks of treatment.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Arteriosclerosis Obliterans</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>250 mg Bid, PO after breakfast and dinner.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Changtai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol+Probucol</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>Pletaal and Changtai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Routine treatment</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Routine treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40~75-year-old male or female&#xD;
&#xD;
          -  Clarified diagnosis of type 2 diabetes mellitus&#xD;
&#xD;
          -  Arteriosclerosis obliterans (ASO) is diagnosed (ASO diagnoses should meet at least one&#xD;
             of the conditions as below:&#xD;
&#xD;
               -  ABI&lt;1.0;&#xD;
&#xD;
               -  The pulse of popliteal artery or dorsalis pedis artery is weeken significantly or&#xD;
                  is different between left and right sides&#xD;
&#xD;
               -  Intermittent claudication, diagnosed as ASO by doctor&#xD;
&#xD;
               -  Ultrasonogram showed that there was atherosclerotic plaque in lower limb within 1&#xD;
                  year&#xD;
&#xD;
          -  Informed Consent Form Signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has an allergic history to study drugs&#xD;
&#xD;
          -  Use one of the following drugs: other antiplatelet or anticoagulation agents except&#xD;
             Aspirin, other hypolipidemic agents except Statins&#xD;
&#xD;
          -  Type 1 diabetes mellitus, specific diabetes mellitus, or gestational diabetes mellitus&#xD;
&#xD;
          -  Has severe ASO above Fontaine IIb,&#xD;
&#xD;
          -  Hemorrhagic tendency or hemorrhagic disease (such as gastrointestinal tract&#xD;
             hemorrhage, etc.)&#xD;
&#xD;
          -  Had a myocardial infarction, angina pectoris, or cerebral infarction within the last 3&#xD;
             months&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Is pregnant, or potentially pregnant, or breastfeeding&#xD;
&#xD;
          -  Severe hepatic insufficient or severe renal insufficiency (AST or ALT is 2.5 times&#xD;
             higher than the upper limit of the normal value range, or serum creatinine is 1.2&#xD;
             times higher than the upper limit of the normal value range)&#xD;
&#xD;
          -  Persistent or hardly controlled hypertension (such as malignant hypertension, BP&gt;&#xD;
             160/100 mmHg)&#xD;
&#xD;
          -  Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular&#xD;
             contractions)&#xD;
&#xD;
          -  Has a medical history that includes a cardiac syncope or a primary syncope&#xD;
&#xD;
          -  Has conditions that may prolong QT interval (such as congenital long QT syndrome,&#xD;
             taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.)&#xD;
&#xD;
          -  Has severe complications (such as diabetes mellitus ketoacidosis, nonketotic&#xD;
             hyperosmolar diabetic coma, malignant tumor, severe anaemia, severe hematologic&#xD;
             diseases, etc.)&#xD;
&#xD;
          -  Other conditions that would exclude the subject from this study by doctor's judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohui Guo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>No 1 Hospital of Peking University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <last_update_submitted>April 21, 2010</last_update_submitted>
  <last_update_submitted_qc>April 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Quanjie Wei</name_title>
    <organization>Otsuka Beijing Research Institute</organization>
  </responsible_party>
  <keyword>type 2 diabetes mellitus, with Arteriosclerosis obliterans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis Obliterans</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

